feed
S&P 500
NASDAQ
DOW
VIX
US10Y
EUR/USD
GOLD
WTI
BTC
AArphra
Arphra/Issuer/WANBURY.BO

WANBURY.BO

Wanbury Limited
HealthcareDrug Manufacturers - Specialty & GenericININRCountry macro →
$258.30
Jun 02, 2026
AI Brief
Revenue · FY
$6.5B
Net income
$661.35M
FY 2026
EPS · diluted
$19.42
EBITDA
$1.07B

Explain this page

Arphra AI

Company profile

DB · companies + sec_company_profile + company_profiles

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Headquarters
BSEL Tech Park, B-Wing, Navi Mumbai, 400703
IN
Phone
91 22 6794 2222
AI description
Arphra AI
Loading cached description…

Identifiers

  • SymbolWANBURY.BO
  • Legal nameWanbury Limited
  • CEOPradeep Patni
  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CountryIN
  • CurrencyINR
  • ExchangeBSE
  • IPO dateFeb 07, 2005
  • CIK
  • ISININE107F01022
  • CUSIP
  • LEI
  • Employees1,491

Trading

DB · key_metrics_ttm
  • Market cap$8.97B
  • P/E (TTM)
  • P/B
  • EV / EBITDA
  • Dividend yield